Evidence map›Paper›PMID 25565203›Full record

Trial reportCell metabolism2015

Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.

Aaron M Cypess, Lauren S Weiner, Carla Roberts-Toler, Elisa Franquet Elía, Skyler H Kessler, Peter A Kahn, Jeffrey English, Kelly Chatman, Sunia A Trauger, Alessandro Doria and 1 more

3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Cell metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 595 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
595citing papers in PubMed, 1 pooled it
60.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03189511 phase4completedstarted 2017, after this paper: background citation

Short Term Effect of Fluvastatin on Brown Adipose Tissue Thermogenesis and Activity in Humans

Ran2017Enrolled17Registered outcomes6Posted comparisons0ConditionsAdipose Tissue, Brown, Clinical Trial, Insulin ResistanceArmsFluvastatin
Open the trial in the graph
NCT01783470 phase2completednot on this map

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

TypeinterventionalSponsorAaron CypessRan2013 to 2014Enrolled15ConditionsObesityArmsbeta3-adrenergic receptor agonist
NCT02354807 phase2unknown statusnot on this map

Efficacy of Pharmacological Stimulation of Brown and White Fat in Lean and Obese Young Adults

TypeinterventionalSponsorOtto MuzikRan2015 to 2018Enrolled20ConditionsBrown FatArmsMirabegron, Cold exposure
3 · Its place in the literature

Who cites it

595 citing papers in PubMed, 1 synthesis or guideline pooled it, 994 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Improving incretin-mediated body weight loss via energy expenditure.Trends in endocrinology and metabolism: TEM · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Junctophilin-2-orchestrated calcium signalosome regulates brown adipocyte thermogenesis and energy metabolism.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  15. Parathyroid hormone enhances appetite and fails to reduce adiposity in ob/ob mice.Pflugers Archiv : European journal of physiology · 2026
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

535 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Aaron M CypessSection of Integrative Physiology and Metabolism, Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: Aaron.Cypess@joslin.harvard.edu.
Lauren S WeinerSection of Integrative Physiology and Metabolism, Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.
Carla Roberts-TolerSection of Integrative Physiology and Metabolism, Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.
Elisa Franquet ElíaDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Skyler H KesslerSection of Integrative Physiology and Metabolism, Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.
Peter A KahnAlbert Einstein College of Medicine, Bronx, NY 10461, USA.
Jeffrey EnglishDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Kelly ChatmanSmall Molecule Mass Spectrometry Facility, FAS Division of Science, Harvard University, Cambridge, MA 02138, USA.
Sunia A TraugerSmall Molecule Mass Spectrometry Facility, FAS Division of Science, Harvard University, Cambridge, MA 02138, USA.
Alessandro DoriaSection of Genetics and Epidemiology, Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.
Gerald M KolodnyDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Joslin Diabetes Center · USBeth Israel Deaconess Medical Center · USHarvard University · USAlbert Einstein College of Medicine · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
Physiological Responses to Activation of Human Brown Adipose TissueZIADK075116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI CYPESS, AARON · 2015 to 2025
$6.1M
Human Brown Adipose Tissue and its Impact on MetabolismK23DK081604 · NIDDK · JOSLIN DIABETES CENTER · PI CYPESS, AARON MARTIN · 2009 to 2013
$764k
Intramural NIH HHS Z99 DK999999NCATS NIH HHS UL1 TR000170NCATS NIH HHS UL1TR000170NCATS NIH HHS UL1 TR001102NCATS NIH HHS UL1TR001102NCRR NIH HHS UL1 RR025758NIDDK NIH HHS K23 DK081604NIDDK NIH HHS K23DK081604NIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

Increasing energy expenditure through activation of endogenous brown adipose tissue (BAT) is a potential approach to treat obesity and diabetes. The class of β3-adrenergic receptor (AR) agonists stimulates rodent BAT, but this activity has never been demonstrated in humans. Here we determined the ability of 200 mg oral mirabegron (Myrbetriq, Astellas Pharma, Inc.), a β3-AR agonist currently approved to treat overactive bladder, to stimulate BAT as compared to placebo. Mirabegron led to higher BAT metabolic activity as measured via (18)F-fluorodeoxyglucose ((18)F-FDG) using positron emission tomography (PET) combined with computed tomography (CT) in all twelve healthy male subjects (p = 0.001), and it increased resting metabolic rate (RMR) by 203 ± 40 kcal/day (+13%; p = 0.001). BAT metabolic activity was also a significant predictor of the changes in RMR (p = 0.006). Therefore, a β3-AR agonist can stimulate human BAT thermogenesis and may be a promising treatment for metabolic disease.

Indexed as

AcetanilidesAdipose Tissue, BrownAdrenergic AgonistsBasal MetabolismChromatography, High Pressure LiquidFluorodeoxyglucose F18GlucoseHumansMaleObesityPositron-Emission TomographyReceptors, Adrenergic, beta-3Tandem Mass SpectrometryThiazolesTomography, X-Ray ComputedYoung AdultAcetanilidesAdrenergic AgonistsFluorodeoxyglucose F18GlucosemirabegronReceptors, Adrenergic, beta-3Thiazoles

Identifiers

PMID25565203
PMCPMC4298351
OpenAlexW2164410780

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.